Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 2,336 | 3,449 | 4,175 | 3,396 | 3,381 | 3,398 | 3,665 | 3,737 |
| Operating profit | €m | 626 | 639 | ||||||
| Net profit | €m | 210 | 319 | 678 | 205 | 84 | 149 | 219 | - |
| EPS reported | € | 0.43 | 0.63 | ||||||
| Operating cashflow per share | € | 1.83 | 2.17 | ||||||
| Capex per share | € | 1.23 | 1.16 | ||||||
| FCF per share | € | 0.60 | 1.02 | ||||||
| Free cash flow | €m | 206 | 345 | ||||||
| Net debt | €m | 3,731 | 3,742 | ||||||
| Book value equity | €m | 2,706 | 2,983 | ||||||
| Book value per share | € | 7.84 | 8.64 | ||||||
| Number of shares | m | 345.23 | 345.26 | ||||||
| DPS (TTM paid) | € | 0.15 | 0.15 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 114.99 | 85.34 | ||||||
| P/B LTM | x | 6.31 | 27.80 | ||||||
| P/S LTM | x | 5.02 | 22.62 | ||||||
| P/FCF LTM | x | 82.98 | 240.49 | ||||||
| EV/EBITDA LTM | x | 20.22 | 81.43 | ||||||
| EV/Sales LTM | x | 6.12 | 23.98 | ||||||
| Earnings Yield LTM | % | 0.87% | 1.17% | ||||||
| FCF Yield | % | 1.21% | 0.42% | ||||||
| Quality | |||||||||
| ROE | % | 5.50% | 7.81% | ||||||
| ROIC | % | 4.93% | 5.27% | ||||||
| Operating margin | % | 18.41% | 17.81% | ||||||
| Gross margin | % | 46.26% | 45.43% | ||||||
| FCF/Sales | % | 6.05% | 9.61% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +79.17% | +61.54% | ||||||
| Sales Growth YoY | % | +0.53% | +4.27% | ||||||
| Net Income Growth YoY | % | +77.13% | +29.30% | ||||||
| FCF Growth | % | -63.69% | +1.84% | ||||||
| Operating Profit Growth | % | +43.11% | +14.74% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.29% | 0.26% | ||||||
| Dividend Growth | % | +0.70% | +0.70% | ||||||
| Payout Ratio | % | 32.81% | 23.36% | ||||||
| FCF/Debt | x | 0.05 | 0.09 | ||||||
| Net Debt/EBITDA | x | 3.64 | 3.41 | ||||||
| EBIT/Net interest | x | 3.29 | 2.88 | ||||||
| Net debt/market cap | % | 21.86% | 4.51% | ||||||
| Net debt/Equity | x | 1.38 | 1.25 | ||||||
| Gross debt/equity | x | 1.58 | 1.33 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection, it provides biosensors, compliance instruments, system software, label-free detection technologies, and SPR systems. In cell analysis, Sartorius offers live-cell analysis platforms, flow cytometry systems, and specialized cell analysis reagents and consumables. Its media and reagent segment includes a wide array of formulations for antibody and recombinant protein production, viral vaccines, regenerative medicine, and stem cell cultivation, along with downstream buffers, microcarriers, strong acids, bases, alcohols, and detergents. The company manufactures various bioreactor systems, from multi-parallel and benchtop units to single-use, stainless steel, cell culture, and microbial bioreactors, all supported by dedicated software applications. Its extensive filtration product line features membranes, blotting products, filter papers, and glass and quartz microfibre products, alongside a comprehensive range of filtration devices for ultrafiltration, sterile filtration, harvesting, analytical and diagnostic sample preparation, particle analysis, pharmaceutical applications, protein/DNA concentration, venting, clarification, and membrane chromatography. Sartorius also delivers solutions for process filtration, process chromatography, fluid management, and cutting-edge process analytical technology with data analytics. Complementary laboratory equipment includes industrial microbiology systems, water purification units, precision weighing and pipetting/dispensing systems, OEM components, and centrifuges. Beyond its products, Sartorius provides essential services such as bioprocess development and engineering, protein expression system optimization, media and process development, comprehensive testing, instrument support, and validation. These offerings primarily serve the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industrial sectors across the globe.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection, it provides biosensors, compliance instruments, system software, label-free detection technologies, and SPR systems. In cell analysis, Sartorius offers live-cell analysis platforms, flow cytometry systems, and specialized cell analysis reagents and consumables. Its media and reagent segment includes a wide array of formulations for antibody and recombinant protein production, viral vaccines, regenerative medicine, and stem cell cultivation, along with downstream buffers, microcarriers, strong acids, bases, alcohols, and detergents. The company manufactures various bioreactor systems, from multi-parallel and benchtop units to single-use, stainless steel, cell culture, and microbial bioreactors, all supported by dedicated software applications. Its extensive filtration product line features membranes, blotting products, filter papers, and glass and quartz microfibre products, alongside a comprehensive range of filtration devices for ultrafiltration, sterile filtration, harvesting, analytical and diagnostic sample preparation, particle analysis, pharmaceutical applications, protein/DNA concentration, venting, clarification, and membrane chromatography. Sartorius also delivers solutions for process filtration, process chromatography, fluid management, and cutting-edge process analytical technology with data analytics. Complementary laboratory equipment includes industrial microbiology systems, water purification units, precision weighing and pipetting/dispensing systems, OEM components, and centrifuges. Beyond its products, Sartorius provides essential services such as bioprocess development and engineering, protein expression system optimization, media and process development, comprehensive testing, instrument support, and validation. These offerings primarily serve the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industrial sectors across the globe.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free